Skip to main content

Invest

Access high quality investment opportunities and invest alongside real investors, real institutions and most importantly, with the same rights. Seed to expansion, our companies go through thorough due diligence assisted by the expertise of our partners at Acceleris Capital.

Step one

Register today

Opportunities to invest through InvestingZone are only available to self certified high-net-worth, self certified professional and restricted investors. Please take a couple of minutes to register and you will have full access to the site and will soon be receiving notifications of investment opportunities.

Step two

Create your portfolio

Investing in early stage business is risky. It is always advisable to create a portfolio so that the associated risk can be spread.

Step three

Monitor and engage

InvestingZone allows you to keep track of progress with your portfolio in your own personal portal. All companies raising funds through IZ agree to use our reporting and shareholder communication tools. These tools build the interaction between companies and shareholders that promotes good governance and control.

Latest Investment Opportunities

Reliance on the promotions below for the purpose of buying shares in unlisted companies will expose you to significant risk of losing all of the property invested. Please read and understand the risk warnings.

  • Stuff of Life Limited

    Secret Saviours is innovative wearable technology. It is the ONLY clinically proven product that can PREVENT pregnant women developing stretch marks. 

    Target
    £175,000
    Committed
    £175,810
    100%
  • Acceleris Capital
    Funnel Music Ltd

    Funnel Music is developing a 'World without Labels' through the most disruptive business model in music for the last 30 years 

    Target
    £90,000
    Committed
    £72,000
    80%
  • Funded
    Acceleris Capital
    Bivictrix Therapeutics Limited

    Developing The Next Generation of Precision ADCs 

    Target
    £430,000
    Committed
    £451,506
    105%
  • Funded
    Acceleris Capital
    YProTech Limited

    YProTech is a leading UK based Chemistry Services Contract Research Organisation (CRO) servicing pharmaceuticals, biotechnology and applied chemistry sectors 

    Target
    £134,000
    Committed
    £234,438
    175%
    EIS
  • Acceleris Capital
    ADC Biotechnology Limited

    ADC Biotech's patented 'Lock-Release' platform addresses problems with the development of ADCs - the Next Generation of Blockbuster Cancer Therapeutics 

    Target
    £4,500,000
    Committed
    £4,397,705
    98%
    EIS

With Compelling Tax Incentives

50%

Upfront income tax relief under the SEIS scheme

30%

Upfront income tax relief under the EIS scheme

100%

Capital gains tax exemption on realisation

100%

Inheritance Tax (IHT) exemption

45%

Maximum loss relief available

Unlimited

Capital gains tax deferral

Learn more

Advisory Panel and Key Investors

InvestingZone is the first platform to receive considerable support from one of the nations leading Corporate Finance Houses, Acceleris Capital.

  • Seneca Partners
  • Acceleris
  • finnCap
  • Enterprise Investment Schema Association
  • Profile image

    Jon Moulton

  • Profile image

    Bob Holt

  • Profile image

    Richard Manley

  • Profile image

    Ron Armstrong

  • Profile image

    Richard Matthewman

  • Profile image

    Ian Currie

Learn more

Corporate Finance, Venture Capital and Angel Networks.

Join other top tier firms in harnessing the power of InvestingZone's professional investment market and amplify your own network of investors.

Attract client companies • Invite further investment • Close more deals • Raise your profile.

 

Learn more

Blog

BIVICTRIX ANNOUNCE £0.5M SEED FUNDING FOR TARGETED CANCER DRUG RESEARCH

BiVicTriX Therapeutics (“BVX”) has today announced the completion of a successful fundraise to develop a new class of targeted cancer drugs. The company’s ‘Dual Targeting Approach’ is designed to give...

Guest Blog - Growth Tips for the UK SME

With three in five small firms expecting to grow their companies in 2017 - and business confidence remaining robust according to research from the Federation of Small Business - it is vital that SMEs ...

Is this Unusual Method the End to Stretch Marks?

The accepted bi-product of pregnancy still strikes fear into the majority of pregnant women in the UK. Current estimates suggest between 75% and 90% of women will develop stretch marks during their pr...